Pertinent grade 3‐4 adverse events occurring in more than 10% of patients included neutropenia (16%), fever and neutropenia (10%), anemia (10%), thrombocytopenia (10%), elevated AST (23%), elevated ALT (10%), hypophosphatemia (10%), and fatigue (13%). This evidence concerns the gene GPT and Thrombocytopenia.